Oral Wegovy proves mettle, now next generation should complement
04/11/26 -"The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being overly conservative, the management upgraded its ..."
Pages
75
Language
English
Published on
04/11/26
You may also be interested by these reports :
04/11/26
The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being ...
04/11/26
“If a man knows not to which port he sails, no wind is favourable.” The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) ...
04/11/26
BioNTech’s Q3 operational performance exceeded expectations, driven by higher outlicensing sales from Bristol-Myers Squibb. 2026 sales guidance was ...
03/11/26
The Q3 results were reassuring, as growth in subcutaneous immunoglobulins, higher volumes and plasma cost optimisation aided expansion in top-line as ...